NCT05353439 2026-03-18
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT05627245 2026-03-18
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03217253 2020-02-07
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Withdrawn